Sanofi (SAN)won U.S. backing to sell the multiple sclerosis pill Aubagio, enabling the drugmaker to enter a $12 billion industry, even as analysts said the medicine may be overshadowed by more effective products.
The Food and Drug Administrationapproved the once-a-day medicine for relapsing forms of the debilitating disease, the agency said yesterday in a statement. The treatment, also known by the scientific name of teriflunomide, is for patients in the initial phases of the disease, Paris-based Sanofi said.
Read the full story: http://bloom.bg/NpoBdr
Source: Bloomberg
Hospitals Report Declining Cash Reserves, Increasing Reimbursement Delays and Denials
December 1st 2023A new report highlighting the twin pressures hospitals have faced over the last 18 months shows that as reimbursement delays and denials increased and cash and investments decreased, operating expenses have risen sharply.
Read More